NCT02782221View on ClinicalTrials.gov

Lipolytic Effects of GH in Human Subjects in Vivo

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 30, 2016

Primary Completion Date

September 22, 2016

Study Completion Date

January 15, 2017

Conditions
Metabolic DiseasesGrowth Hormone Treatment
Interventions
DRUG

Growth Hormone

Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg

DRUG

Pegisomant

One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone

Trial Locations (1)

8000

University Hospital of Aarhus, Aarhus

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT02782221 - Lipolytic Effects of GH in Human Subjects in Vivo | Biotech Hunter | Biotech Hunter